Yungjin Pharm영진약품
003520 · KOSPI · ₩003520 · 영진약품
₩955▲ ₩10 (1.06%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 29.5% | 30.3% | 31.9% | 30.7% | 29.6% | 29.5% |
| Operating margin | −1.7% | 1.3% | 3.5% | 1.3% | −3.4% | −7.1% |
| Net margin | −2.5% | −0.1% | 0.5% | −1.6% | −10.1% | −5.9% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −0.5% | +0.9% | +7.3% | +7.6% | +11.4% | — |
| Operating income growth | −227.0% | −60.8% | +179.8% | +142.3% | +46.9% | — |
| Net income growth | −2,648.0% | −118.5% | +131.8% | +82.4% | −89.6% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −7.0% | −0.3% | 1.4% | −4.3% | −22.6% | −11.0% |
| Return on assets | −2.6% | −0.1% | 0.5% | −1.8% | −11.1% | −6.0% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 163.9% | 186.9% | 160.9% | 152.8% | 126.0% | 85.1% |
| Net debt to equity | 58.7% | 46.8% | 67.9% | 64.9% | 42.2% | 10.3% |
| Current ratio | 147.3% | 147.8% | 108.0% | 168.6% | 205.9% | 185.6% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Yungjin Pharm / 영진약품 / 003520 / KRX:003520
Source: KRX statistical information